AU2023229152A1 - Abiraterone decanoate prodrugs and use in therapy - Google Patents

Abiraterone decanoate prodrugs and use in therapy Download PDF

Info

Publication number
AU2023229152A1
AU2023229152A1 AU2023229152A AU2023229152A AU2023229152A1 AU 2023229152 A1 AU2023229152 A1 AU 2023229152A1 AU 2023229152 A AU2023229152 A AU 2023229152A AU 2023229152 A AU2023229152 A AU 2023229152A AU 2023229152 A1 AU2023229152 A1 AU 2023229152A1
Authority
AU
Australia
Prior art keywords
abiraterone
human subject
pharmaceutical composition
decanoate
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2023229152A
Other languages
English (en)
Inventor
Jr. William R. Moore
Matthew J. Sharp
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Astellas US LLC
Original Assignee
Astellas US LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas US LLC filed Critical Astellas US LLC
Publication of AU2023229152A1 publication Critical patent/AU2023229152A1/en
Assigned to ASTELLAS US LLC reassignment ASTELLAS US LLC Amend patent request/document other than specification (104) Assignors: PROPELLA THERAPEUTICS, INC.
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2023229152A 2022-03-01 2023-02-15 Abiraterone decanoate prodrugs and use in therapy Pending AU2023229152A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202263315240P 2022-03-01 2022-03-01
US63/315,240 2022-03-01
US202263425839P 2022-11-16 2022-11-16
US63/425,839 2022-11-16
PCT/US2023/013116 WO2023167783A1 (en) 2022-03-01 2023-02-15 Abiraterone decanoate prodrugs and use in therapy

Publications (1)

Publication Number Publication Date
AU2023229152A1 true AU2023229152A1 (en) 2024-09-05

Family

ID=85724851

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2023229152A Pending AU2023229152A1 (en) 2022-03-01 2023-02-15 Abiraterone decanoate prodrugs and use in therapy

Country Status (12)

Country Link
US (1) US20250186463A1 (cg-RX-API-DMAC7.html)
EP (1) EP4486353A1 (cg-RX-API-DMAC7.html)
JP (1) JP2025508944A (cg-RX-API-DMAC7.html)
KR (1) KR20240167653A (cg-RX-API-DMAC7.html)
CN (1) CN119136813A (cg-RX-API-DMAC7.html)
AU (1) AU2023229152A1 (cg-RX-API-DMAC7.html)
CA (1) CA3243913A1 (cg-RX-API-DMAC7.html)
CL (1) CL2024002613A1 (cg-RX-API-DMAC7.html)
CO (1) CO2024013267A2 (cg-RX-API-DMAC7.html)
IL (1) IL315174A (cg-RX-API-DMAC7.html)
MX (1) MX2024010741A (cg-RX-API-DMAC7.html)
WO (1) WO2023167783A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021338271A1 (en) * 2020-09-02 2023-03-30 Astellas Us Llc Abiraterone prodrugs

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201207886D0 (en) * 2012-05-04 2012-06-20 Jagotec Ag Improvements in or relating to organic compounds
AU2019362061B2 (en) 2018-10-18 2024-09-26 Essa Pharma Inc Androgen receptor modulators and methods for their use
CN114026106B (zh) * 2019-03-06 2025-01-21 普洛拉治疗公司 阿比特龙前药
CN117120034A (zh) 2021-02-15 2023-11-24 普洛佩拉治疗公司 阿比特龙前药
WO2023038933A1 (en) * 2021-09-08 2023-03-16 Propella Therapeutics, Inc. Oral abiraterone formulations

Also Published As

Publication number Publication date
MX2024010741A (es) 2024-09-10
CA3243913A1 (en) 2023-09-07
IL315174A (en) 2024-10-01
CO2024013267A2 (es) 2024-10-10
WO2023167783A1 (en) 2023-09-07
CL2024002613A1 (es) 2025-02-07
US20250186463A1 (en) 2025-06-12
CN119136813A (zh) 2024-12-13
EP4486353A1 (en) 2025-01-08
KR20240167653A (ko) 2024-11-27
JP2025508944A (ja) 2025-04-10

Similar Documents

Publication Publication Date Title
US11957696B2 (en) Abiraterone prodrugs
US12138273B2 (en) Abiraterone prodrugs
US20240050447A1 (en) Abiraterone prodrugs
US20250025417A1 (en) Oral abiraterone formulations
US20250186463A1 (en) Abiraterone decanoate prodrugs and use in therapy
WO2024107928A1 (en) Abiraterone decanoate composition and use in therapy
HK40120426A (en) Abiraterone prodrugs
HK40096901A (en) Abiraterone prodrugs
HK40096900A (en) Abiraterone prodrugs
HK40130201A (en) Abiraterone prodrugs
HK40129794A (zh) 阿比特龙前药
HK40103488A (en) Abiraterone prodrugs
HK40065545B (en) Abiraterone prodrugs

Legal Events

Date Code Title Description
HB Alteration of name in register

Owner name: ASTELLAS US LLC

Free format text: FORMER NAME(S): PROPELLA THERAPEUTICS, INC.